WO2006033386A1 - 安定化されたヒトIgG4抗体 - Google Patents
安定化されたヒトIgG4抗体 Download PDFInfo
- Publication number
- WO2006033386A1 WO2006033386A1 PCT/JP2005/017463 JP2005017463W WO2006033386A1 WO 2006033386 A1 WO2006033386 A1 WO 2006033386A1 JP 2005017463 W JP2005017463 W JP 2005017463W WO 2006033386 A1 WO2006033386 A1 WO 2006033386A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- heavy chain
- seq
- constant region
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to a mutated IgG4 obtained by introducing a mutation into the constant region of HI HgG4 and having improved physical properties.
- Immunoglobulins are glycoproteins present in serum and tissue fluids of all mammals and have a function of recognizing foreign antigens. Antibody binding to antigen activates the complement system and promotes cell phagocytosis, antibody-dependent cytotoxicity, mediator release, and antigen presentation through the Fc receptor (FcR) present on the cell surface Involved in biological defense through activation of effector functions.
- FcR Fc receptor
- IgG human immunoglobulins
- IgA immunoglobulins
- IgM immunoglobulins
- IgD immunoglobulins
- IgG can be further divided into four subclasses consisting of IgGl, IgG2, IgG3 and IgG4, and IgA can be further divided into two subclasses which also have IgAl and IgA2 strength.
- the basic structure of an immune globulin consists of two homologous light chains (light chains) and two homologous heavy chains (heavy chains). Immunoglobulin class and subclass are determined by the heavy chain.
- each immunoglobulin has a different function. For example, complement binding ability increases in the order IgM> IgG3> IgGl> IgG2, and affinity to FeyRI (Fc receptor I) increases in the order of IgG3> IgGl> IgG4> IgG2.
- IgG1, IgG2 and Ig G4 can bind to protein A.
- CD40 plays an important role as a gene that regulates immunity as such an antigen.
- Anti-CD40 antibodies that inhibit the binding of CD40 ligand to CD40 are considered to have high potential as pharmaceuticals.
- CD40 is expressed in a wide variety of cells other than immune cells. If the function causes damage to CD40-expressing cells, it may cause severe side effects. Therefore, it is considered that the antibody against such an antigen is preferably IgG4.
- IgG4 is a half antibody that does not have SS bonds between H chains in vivo (normally an antibody consists of two L chains and two H chains, but a half antibody consists of one L chain and one H chain. In the same way, half antibodies are produced even when expressed in animal cells such as CHO for the production of pharmaceuticals.
- the formation of half-antibodies is a very alarming issue in terms of pharmaceutical manufacturing, but it has been reported that half-antibody formation can be suppressed by introducing a single amino acid substitution in the constant region. (See Non-Patent Document 1).
- IgG4 has a weaker antibody-dependent cytotoxic effect than IgGl, but it has weak FcR binding. However, this binding to FcR can be further reduced and improved by introducing a mutation into the hinge region of IgG4 (see Patent Documents 1 to 3).
- IgG4 It is possible to produce IgG4 close to the ideal by the above-described method. In manufacturing as a pharmaceutical product, there are still problems to be overcome. It is the instability of IgG4 antibodies at low pH. In general, when an antibody is produced as a pharmaceutical product, a method of affinity purification using protein A is used. At this time, in order to elute the antibody bound to protein A, a low pH buffer is often used. In order to remove viruses, it is desirable to treat at low pH for a certain period of time. However, as shown in the present invention, it has been found that IgG4 antibodies tend to form aggregates that are less stable at low pH than IgGl antibodies. This is due to the presence of aggregates in pharmaceutical products. Thus, it has been reported that infusion reaction, complement activation, or antibody-dependent cytotoxicity is enhanced, and it is easily estimated that these lead to side effects. For this reason, it is very important to reduce the amount of aggregates as much as possible.
- Patent Document 1 Japanese Patent No. 3101690
- Patent Document 2 US5648260
- Patent Document 3 US5624821
- Non-patent literature l S. Angal et., Al. Molecular Immunology 1993, 30, 105-108
- An object of the present invention is to produce a highly stable variant of the human antibody IgG4.
- CDC activity can be reduced by replacing D270, K322, P329, and P331 with A or converting P331 into S or G.
- ADCC activity can be reduced by substituting E for L235 and A for G237.
- E for L235 and A for G237.
- R 409th arginine
- K lysine
- T threonine
- M methionine
- L leucine substituted heavy chain constant regions of IgG4, including fusion proteins that contain at least a portion with a CH3 domain, preferably the portion further includes a hinge region and a CH2 domain .
- the present invention is as follows.
- variable region of the heavy chain amino acid sequence shown in SEQ ID NO: 2 and the variable region of the light chain amino acid sequence shown in SEQ ID NO: 4 bind to the heavy chain constant region and human light chain constant region of HgG4, respectively.
- the heavy chain variable region encoded by the heavy chain nucleic acid sequence shown by SEQ ID NO: 1 and the light chain variable region encoded by each light chain acid sequence shown by SEQ ID NO: 3 are each a heavy chain of human IgG4. And the light chain constant region to form a heavy chain and a light chain.
- the 228th serine of the heavy chain constant region shown by the EU index by Kabat et al. Becomes proline and the 235th leucine becomes glutamic acid.
- the antibody of [1], which is substituted, [6] In the heavy chain represented by SEQ ID NO: 44, in the heavy chain constant region shown by the EU index by Kabat et al., The 228th serine is proline, the 235th leucine is glutamic acid, and the 409th arginine is lysine, threonine,
- Heavy chain constant sequence with 228th serine in the heavy chain constant region indicated by the U index substituted with proline, 235th leucine with glutamic acid, and 409th arginine with lysine, threonine, metyon or leucine
- the antibody of [1] having a light chain encoded by the nucleic acid sequence represented by number 45,
- a method for producing an antibody comprising a step of substituting 409th arginine with lysine, threonine, methionine or leucine for the heavy chain constant region of HI HgG4, as indicated by the EU index by Kabat et al.
- an expression vector having a gene encoding a heavy chain and a light chain is prepared, the expression vector is introduced into a host, and the host is A method for producing an antibody, which comprises culturing and obtaining a culture force,
- An expression vector having a variable region of the heavy chain nucleic acid sequence represented by SEQ ID NO: 1 and a variable region of the light chain nucleic acid sequence represented by SEQ ID NO: 3 is prepared, the expression vector is introduced into the host, Culturing and obtaining the antibody from the culture, an antibody production method,
- An expression vector having a heavy chain nucleic acid sequence represented by SEQ ID NO: 47 and a light chain nucleic acid sequence represented by SEQ ID NO: 45 is prepared, the expression vector is introduced into a host, the host is cultured, Obtaining the antibody, a method for producing the antibody,
- a pharmaceutical composition comprising the antibody according to any one of [3] to [7] as an active ingredient, and
- Transplant rejection autoimmune disease, cancer, comprising as an active ingredient the antibody of any of [3] to [7] A therapeutic agent for arteriosclerosis, nephritis, Alzheimer's disease or amyloidosis.
- the 409th arginine (R) in human IgG4 is lysine (K), threonine (T), methionine
- the antibody of the present invention substituted with (M) or leucine (L) has a feature that aggregate formation, particularly aggregate formation at low pH is reduced while retaining binding to an antigen. Therefore, the antibody of the present invention can be stably produced as a pharmaceutical product. Furthermore, when administered to a subject, it is easy to avoid side effects caused by contamination with antibody aggregates and can be used safely.
- FIG. 1A is a diagram showing by binding activity that there is no change in antibody binding by changing the primary structure of the constant region.
- FIG. 1B is a diagram showing by binding activity that there is no change in antibody binding by changing the primary structure of the constant region.
- FIG. 1C is a diagram showing by binding activity that there is no change in antibody binding by changing the primary structure of the constant region.
- FIG. 2A is a graph showing that the antagonistic activity of anti-CD40 antibody is not changed by changing the primary structure of the constant region, based on the antagonistic activity (Ramos cell assembly).
- FIG. 2B is a diagram showing that the antagost activity of the anti-CD40 antibody is not changed by changing the primary structure of the constant region, based on the antagost activity (Ramos cell assembly).
- FIG. 2C is a diagram showing that the antagost activity of the anti-CD40 antibody is not changed by changing the primary structure of the constant region, based on the antagost activity (Ramos cell assembly).
- FIG. 2D is a diagram showing that the antagonistic activity of the anti-CD40 antibody is not changed by changing the primary structure of the constant region, based on the antagonistic activity (Ramos cell assembly).
- the H chain has two region forces, a variable region that determines the binding specificity to an antigen and a constant region that is involved in the expression of an effector function of an antibody.
- the variable region is a part of it. Due to the recombination of genes and the introduction of somatic mutation, the sequence of the antigen binding site differs structurally. This brings about the feature that a large number of foreign antigens can be recognized.
- an antibody since an antibody is a molecule that primarily controls a biological defense function against foreign microorganisms, viruses, and cancers, it also has a function of killing and removing cells to which the antibody is bound, and this is called an effector function. .
- ADCC Antibody-Dependent Cellular Cytotoxicity
- CDC complement-dependent cytotoxicity
- ADCC refers to the cytotoxic activity induced by the activation of cells by binding to the antibody constant region via FcR expressed on the surface of macrophage, NK cells, neutrophils, etc.
- CDC refers to the cytotoxic activity caused by the activated complement system when an antibody binds to an antigen.
- IgG4 antibody While maintaining specific binding to an antigen, the stability of IgG4 antibody can be improved. Specifically, 409th arginine (R) of IgG4 is replaced with glutamic acid (E), ferulalanin (F), isoleucine (I), asparagine (N), glutamine (Q), serine (S), parin (V), tryptophan (W), tyrosine (Y), lysine (K), threonine (T), methionine (M), or leucine. Preferred is substitution with lysine (K), threonine (T), methionine (M) or leucine (L), and most preferred is substitution with lysine (K).
- an antibody with improved stability means an antibody that hardly forms an aggregate under acidic conditions, that is, low pH conditions, for example, at PH3.5 for 10 minutes or
- An antibody in which the content of aggregates formed when treated for 60 minutes is 10% or less, preferably 5% or less, and more preferably 1% or less.
- the content of the aggregate is, for example, liquid chromatography Can be measured.
- an antibody having improved physical properties means an antibody in which ADCC and / or CDC is adjusted to a desired strength in addition to stability, and the ability to bind to FcR to a desired level. This refers to a regulated antibody.
- ADCC and / or CDC regulation and FcR binding ability can be regulated by introducing mutations into the antibody as follows.
- ADCC and / or CDC can be reduced or enhanced by further introducing an appropriate mutation into the antibody having improved stability.
- L235, D265, D270, ⁇ 322, ⁇ 331, ⁇ 329 (the alphabet is a single letter of an amino acid.
- the numbers are the EU index by Kabat et al. (Kabat et. Al., Sequences of proteins of Immunological Interest, 1991 Fifth edition) The same shall apply hereinafter) is considered to play an important role in the complement activity of HI HgG, and by substituting this site with another amino acid, CDC activity can be reduced (Esohe).
- Glu233- Ser239, Gly316- Lys338, Lys274- Arg301, Tyr407-Arg416, Asn297, Glu318, Leu234- Ser239, Asp265-Glu269, Asn297-Thr299 and Ala327-Ile332 are involved in the binding of IgG and FcR.
- CDC activity can be enhanced by converting 331st S of IgG4 to P (Yuanyuan Xu et., Al. J Biol. Chem. 1994. 269. 3469-3474).
- the antibody with improved stability there is no limitation on the antibody with improved stability in which the 409th arginine (R) of IgG4 is replaced with lysine (K), threonine (T), methionine (M), or leucine (L).
- An example is anti-CD40 antibody. More specific examples include 4D11, KM281-1-10 and F4-465 described in WO03 / 88186.
- IgG4 R409 is mutated to K at a frequency of 1/45 in humans, there is no description about the mutation and the stability of IgG4 (Molecular characterization of immunogloDulin u4 isoallotype).
- CD40 refers to Clark et al. (EA Clark et. Al., Proc. Natl. Acad. Sci. USA 83: 4494, 1986) or Stamenkovic et al. (I. Stamenkovic et. Al., EMBO J. 8: 1403, 1989), in particular, an antigenic polypeptide expressed on the surface of B cells, DCs, macrophages, endothelial cells, epithelial cells, or their tumor cells. It is.
- Anti-CD40 antibody means a monoclonal antibody and a polyclonal antibody against cell-expressed CD40, full-length CD40 or partial-length CD40. A monoclonal antibody is preferred.
- the “antibody” is derived from genes encoding the heavy chain variable region and heavy chain constant region and the light chain variable region and the light chain constant region constituting immunoglobulin (collectively referred to as "antibody gene”). Is.
- the antibodies of the present invention include antibodies having any immunoglobulin class and isotype.
- CH1 domain refers to a part of the antibody heavy chain constant region, and the EU index of Kabat et al. (Kabat et. Al., Sequences of proteins of immunological interest, 1991 Fifth edition).
- the CHI domain is defined as EU index 118 to 215, the hinge region is defined as EU index 216 to 237, the CH2 domain is defined as EU index 238 to 340, and the CH3 domain is defined as EU index 341 to 446.
- Human antibody means an antibody that is an expression product of a human-derived antibody gene.
- Human antibody light chains can be either ⁇ or E, and human antibody heavy chains are made up of five different classes of IgG, IgA, IgM, IgD, and IgE.
- IgG is further divided into IgG1, IgG2, and IgG3. It consists of four subclasses consisting of IgG4.
- Antibody variant refers to a product in which one or more amino acid deletions, substitutions, insertions or additions have occurred in the amino acid sequence of an antibody produced by Hypridoma.
- the antibody mutant of the present invention is appropriately selected by using a method for isolating antibody genes from hyperidoma, sequence information on human antibody constant regions, a method for site-directed mutagenesis into genes, and the like well known to those skilled in the art. Can be made.
- the antibody of the present invention includes an antibody in which "several" amino acids are deleted or substituted, or "several” amino acids are inserted or added.
- the term “pieces” specifically refers to 1 to 10, preferably 1 to 8, more preferably 1 to 5, and most preferably 1 or 2. These deletions, substitutions, insertions and attachments preferably occur in the antibody heavy chain constant region. Specifically, (1) an antibody in which the 228th serine in the heavy chain constant region indicated by the EU index by Kabat et al. Is replaced with proline, (2) EU by Kabat et al.
- the antibodies of the present invention also include chimeric antibodies and humanized antibodies.
- Chimeric antibodies include portions of antibodies from two or more species (such as mouse antibody variable regions and human antibody constant regions) (such as European patent applications 120694 and 125023).
- Human rabbit antibodies are generated, for example, using mouse CDR grafting techniques, mouse CDRs, human variable region frameworks and constant region primers (Riechmann, et al, Nature (1988), 332, 323-327, etc.).
- an antibody in the present invention, can be obtained by incorporating an antibody gene into an expression vector, introducing the vector into an appropriate host cell, and collecting and purifying the cell or cell culture supernatant. It is out.
- a phage or plasmid that can be autonomously propagated in a host cell or integrated into the host cell chromosome is used.
- plasmid DNA examples include plasmids derived from Escherichia coli, Bacillus subtilis, or yeast.
- phage DNA examples include ⁇ phage.
- the host used for transformation is not particularly limited as long as it can express the target gene. Examples include bacteria (E. coli, Bacillus subtilis, etc.), yeast, animal cells (COS cells, CHO cells, etc.) and insect cells.
- bacteria E. coli, Bacillus subtilis, etc.
- yeast yeast
- animal cells COS cells, CHO cells, etc.
- insect cells insect cells.
- Methods for introducing genes into the host are known, and arbitrary methods (for example, a method using calcium ions, an electoporet method, a spheroplast method, a lithium acetate method, a phosphate power method, a lipofuxion method, etc.) Is mentioned.
- Examples of the method for introducing a gene into an animal described later include a microinjection method, a method for introducing a gene into an ES cell using an erect mouth position or lipofection method, and a nuclear transfer method.
- the “culture” refers to any of (a) culture supernatant, (b) cultured cells or cultured cells or disrupted products thereof, and (c) secreted product of the transformant. Is also meant.
- a medium suitable for the host to be used is used, and a stationary culture method, a culture method using a roller bottle, or the like is employed.
- the antibody is collected by disrupting the cells or cells.
- the target antibody is produced outside the cells or cells, use the culture solution as it is, or remove the cells or cells by centrifugation or the like. Thereafter, the target antibody can be isolated and purified from the culture by using general biochemical methods using various chromatographies used for protein isolation and purification alone or in appropriate combination. Can do.
- an animal host in which the gene of the target antibody is incorporated into an endogenous gene such as Transgenic worm, Transgenic chick, Transgenic chick. It is also possible to produce a di- or transgenic pig and obtain a large amount of monoclonal antibody derived from the antibody gene from milk secreted from the transgenic animal (Wright, G., et al. (1991) Bio / Technology 9, 830-83 4).
- Hypridoma can be grown, maintained and stored in the culture supernatant according to the characteristics of the cell type to be cultured, the purpose of the test study and the culture method. It is possible to carry out using any known nutrient medium such as that used to produce monoclonal antibodies, or any nutrient medium derived from a known basal medium.
- a pharmaceutical composition containing a purified preparation of the antibody of the present invention is also included in the scope of the present invention.
- a pharmaceutical composition preferably includes a physiologically acceptable diluent or carrier in addition to the antibody, and may be a mixture with other drugs or other drugs such as antibiotics.
- Suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline, phosphate buffered saline glucose solution, and buffered saline.
- the antibody may be freeze-dried (freeze-dried) and reconstituted by adding a buffered aqueous solution as described above when needed.
- the routes of administration are oral routes and parenteral routes including intravenous, intramuscular, subcutaneous and intraperitoneal injections or drug delivery.
- the effective amount administered as a combination of an effective amount of the antibody of the present invention and an appropriate diluent and a pharmacologically usable carrier is 0.0001 mg to 100 mg / kg body weight per time. mg, administered every 2 to 8 weeks.
- the anti-CD40 antibody according to the present invention is used for transplant rejection (eg, kidney transplantation, heart transplantation, liver transplantation, pancreas, intestinal transplantation, Xenograft), autoimmune disease (eg, inflammatory bowel disease (eg, Crohn's disease) And ulcerative colitis), systemic lupus erythematosus (SLS), idiopathic thrombocytopenic purpura (ITP), multiple sclerosis, psoriasis and rheumatism), cancer (eg lung cancer, colon cancer, colon cancer, rectal cancer, Spleen cancer, liver cancer, prostate cancer, bladder cancer, breast cancer and stomach cancer), arteriosclerosis, nephritis, Arno, ima disease and amyloidosis.
- transplant rejection eg, kidney transplantation, heart transplantation, liver transplantation, pancreas, intestinal transplantation, Xenograft
- autoimmune disease eg, inflammatory bowel disease (eg, Crohn's disease)
- anti-CD40 antibodies described in WO02 / 088186, antibodies were prepared using the light chain and heavy chain variable regions of 4D11, ⁇ 281-1-10, F4-465. These three antibodies are known to act as antagonists. 4D11, KM281-1-10 and F4-465 are antibodies produced by the hybridomas 4D11, KM281-1-10 and F4-465, respectively.Hybridoma 4D11 has the accession number FERM BP-7758.
- Hypridoma KM281-1-10 is under the accession number FERM BP-7579, and as of May 9, 2001, the National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center (Tsukuba Ito, Ibaraki Prefecture 1 It is deposited at 1-chome 1 center 6).
- F4-465 is deposit number ATCC PTA-3338 with deposit number ATCC PTA-3338, US National Bacteria Collection, Virginia, USA 20110-2209 .
- the translation start point of the heavy chain nucleic acid sequence is an ATG codon starting from the 16th adenine (A) from the 5 'end of SEQ ID NO: 1.
- the boundary between the signal sequence and the variable region is located between the third cytosine (C) and the 94th cytosine (C).
- the border of the region is expected to be located between the 456th adenine (A) and the 457th guanine (G).
- Using gene sequence prediction software (Signal P ver.2)).
- the boundary between the signal sequence and the variable region is located between the 26th serine (S) and the 27th glutamine (Q).
- the region boundary is expected to be located between the 147th serine (S) and the 148th alanine (A).
- nucleic acid sequence of the heavy chain variable region of 4D 11 is from the 94th cytosine (C) to the 456th adenine (A) in SEQ ID NO: 1.
- amino acid sequence of the heavy chain variable region of 4D11 is from the 27th glutamine (Q) to the 147th serine (S) in SEQ ID NO: 2.
- the translation start point of the light chain nucleic acid sequence is an ATG codon starting from the 59th adenine (A) of SEQ ID NO: 3.
- the boundary between the signal sequence and the variable region is located between the 24th thymine (T) and the 125th guanine (G),
- the boundary of the constant region is predicted to be located between the 442nd adenine (A) and the 443rd cytosine (C) (using the gene sequence prediction software (Signal P ver.2)).
- the boundary between the signal sequence and the variable region is located between the 2nd cysteine (C) and the 23rd alanine (A).
- the region boundary is expected to be located between the 128th lysine (K) and the 129th arginine (R).
- the nucleic acid sequence of the light chain variable region of 4D11 has the 125th guanine (G) force in SEQ ID NO: 3 and the 442nd adenine (A).
- the amino acid sequence of the light chain variable region of 4D11 is from the 23rd alanine (A) to 128th lysine (K) in SEQ ID NO: 4.
- 4D11G4 The heavy chain and light chain nucleic acid sequences of an antibody in which the heavy chain constant region of 4D11 is replaced with IgG4 (hereinafter referred to as 4D11G4) are shown below.
- D11G4 heavy chain amino sequence (SEQ ID NO: 44)
- SPVTKSFNRGEC The heavy chain nucleic acid sequence in which the heavy chain constant region of 4D11 is replaced with IgG4, serine at position 228 is replaced with proline, leucine at position 235 is glutamic acid, and arginine at position 409 is replaced with lysine is shown below. 4D11G4PEK).
- the DNAs encoding the heavy chain variable region and light chain variable region of KM281110 and the amino acid sequences of the heavy chain and light chain are shown below.
- the translation start point of the heavy chain nucleic acid sequence is an ATG codon starting from the 52nd adenine (A) from the 5 ′ end of SEQ ID NO: 5.
- the boundary between the signal sequence and the variable region is located between the 108th cytosine (C) and the 109th cytosine (C).
- the constant region are predicted to be located between the 468th adenine (A) and the 469th guanine (G) (using the gene sequence prediction software (Signal P ver.2)).
- the boundary between the signal sequence and the variable region is located between the 19th serine (S) and the 20th glutamine (Q), and is variable.
- the boundary between the region and the stationary region is expected to be located between the 139th serine (S) and the 140th alanine (A)
- the nucleic acid sequence of the heavy chain variable region (mature part) of KM281-1-10 is from the 109th cytosine (C) to the 468th adenine (A) in SEQ ID NO: 5.
- the amino acid sequence of the heavy chain variable region (mature part) of KM281-1-10 is the 20th position in SEQ ID NO: 6. From glutamine (Q) to 139th serine (S).
- the translation start point of the light chain nucleic acid sequence is an ATG codon starting from the 41st adenine (A) of the 5 'terminal force of SEQ ID NO: 7.
- the boundary between the signal sequence and the variable region is located between the 100th adenine (A) and the 101st guanine (G).
- the boundary between the region and the constant region is predicted to be located between the 424th adenine (A) and the 425th cytosine (C) (using the gene sequence prediction software (Signal P ver. 2)).
- the boundary between the signal sequence and the variable region is located between the 20th glycine (G) and the 21st glutamate (E), and is variable.
- the boundary between the region and the constant region is expected to be located between the 128th lysine (K) and the 129th arginine (R).
- the nucleic acid sequence of the light chain variable region (mature part) of KM281-1-10 is from 101st guanine (G) to 424th adenine (A) in SEQ ID NO: 7.
- the amino acid sequence of the light chain variable region (mature part) of KM281-1-10 is from the 21st glutamic acid (E) to the 128th lysine (K) in SEQ ID NO: 8.
- the present invention includes an antibody having the above mature portion, which is stabilized by the above mutation.
- KM281-1-10 nucleic acid sequence (SEQ ID NO: 5)
- the translation start point of the heavy chain nucleic acid sequence is an ATG codon beginning with the 47th adenine (A) from the 5 'end of SEQ ID NO: 9.
- the boundary between the signal sequence and the variable region is located between the 103rd cytosine (C) and the 104th cytosine (C).
- the boundary of the constant region is predicted to be located between the 484th adenine (A) and the 485th guanine (G) (using the gene sequence prediction software (Signal P ver. 2)).
- the boundary between the signal sequence and the variable region is located between the 19th serine (S) and the 20th glutamine (Q). Stationary region The boundary is expected to be located between the 146th serine (S) and the 147th alanine (A).
- the nucleic acid sequence of the heavy chain variable region of F4-465 is from the 104th cytosine (C) to the 484th adenine (A) in SEQ ID NO: 9.
- the amino acid sequence of the heavy chain variable region of F4-465 is from the 20th glutamine (Q) to the 146th serine (S) in SEQ ID NO: 10.
- the translation start point of the light chain nucleic acid sequence is the ATG codon starting with the adenine (A) force at the 81st 5 'end of SEQ ID NO: 11.
- the boundary between the signal sequence and the variable region is located between the 137th cytosine (C) and the 138th thymine (T),
- the boundary of the constant region is predicted to be located between the 458th thymine (T) and the 459th cytosine (C) (using the gene sequence prediction software (Signal P ver.2)).
- the boundary between the signal sequence and the variable region is located between the 19th alanine (A) and the 20th serine (S),
- the boundary of the stationary region is expected to be located between the 126th glycine (G) and the 127th glutamine (Q).
- the nucleic acid sequence of the light chain variable region of F4-465 is from 138th thymine (T) to 458th thymine (T) in SEQ ID NO: 11.
- the amino acid sequence of the light chain variable region of F4-465 is from the 20th serine (S) to the 126th glycine (G) in SEQ ID NO: 12.
- F4-465 heavy chain nucleic acid sequence (SEQ ID NO: 9)
- F4-465 light chain nucleic acid sequence (SEQ ID NO: 11)
- N5KG4PE was prepared by linking to N5KG4PE vector (IDEC Pharmaceuticals) N5KG4PE contains IgG2 constant region and S228P and L235E point mutations.
- the culture supernatant was charged to a Protein A column (Amersham Biosciences) and 0.1M citrate When neutralized by elution with buffer (pH 2.7), the pH is 3.5, and when incubated at 37 ° C for 1 min and 10 min, about 10% of aggregates are formed, whereas the constant region of 4D11 is It has been found that almost no aggregates are formed in 4D114 D11G1, which is IgGl (Japanese Patent Application 2003-4314 08) .To identify the IgGl region that is involved in the suppression of aggregate formation at low pH
- IgG [4/4 / l / l] is N5KG4PE (IDEC Pharmaceuticals) in a saddle type, primer linkH: gggtacgtcctcacattcagtgatcag (SEQ ID NO: 13), 24ch4: AGGGGTCCGGGAGATCAT GAGAGTGTCCTT (SEQ ID NO: 14) at 98 ° C for 1 second, The reaction at 60 ° C for 30 seconds and 72 ° C for 30 seconds was performed 15 times.
- N5KG1- Val Lark (IDEC Pharmaceuticals: hereinafter abbreviated as N5 KG1) is used as a saddle, using primer 24ch3: AAGGACACTCTCATGATCTCCCGG ACCCCT (SEQ ID NO: 15), linkH2: tgatcatacgtagatatcacggc (SEQ ID NO: 16), 98 ° C1 Second, 60 ° C for 30 seconds and 72 ° C for 30 seconds, the reaction was performed 15 times.
- the reaction After purifying the amplified DNA fragment with the PCR purification kit and mixing two equal amounts of the two purified DNA fragments, the reaction at 98 ° C for 1 second, 60 ° C for 30 seconds and 72 ° C for 30 seconds is performed 5 times, and the primers linkH and linkH2 Reacted 15 times.
- the amplified DNA fragment was cut with Nhel and BamHI and replaced with the IgGl constant region of the N5KG1 vector. This expression vector was named N5KG4411.
- IgG [l / l / 4/4] has N5KG1 as a saddle, primer linkH: gggtacgtcctcacattcagtgatc ag (SEQ ID NO: 13), 24ch4: AGGGGTCCGGGAGATCATGAGAGTGTCCTT (SEQ ID NO: In No. 14), the reaction at 98 ° C for 1 second, 60 ° C for 30 seconds and 72 ° C for 30 seconds was performed 15 times.
- primer 24ch3 AAGGACACTCTCATGATCTCCCGGACCCCT (SEQ ID NO: 15)
- linkH2 tgatcatacgtagatatcacggc (SEQ ID NO: 16)
- 15 reactions at 98 ° C for 1 second, 60 ° C for 30 seconds, 72 ° C for 30 seconds went.
- the reaction at 98 ° C for 1 second, 60 ° C for 30 seconds and 72 ° C for 30 seconds is performed 5 times, and the primers linkH and linkH2 are added. In addition, it reacted 15 times.
- the amplified DNA fragment was cut with Nhel and BamHI and replaced with the IgGl constant region of the N5KG1 vector. This expression vector was named N5KG1144.
- IgG [4/4 / l / 4] is N5KG4411 prepared as described above, and the primer linkH: gggtacgtcctcacattcagtgatcag (SEQ ID NO: 13), CH3consR: GGTGTACACCTGTGGC TCTCGGGGCTGCCC (SEQ ID NO: 17) is 98 ° C1 Second, 60 ° C for 30 seconds and 72 ° C for 30 seconds were performed 15 times.
- N5KG4PE as a saddle and primers CH3cons: GGGCAGCCCCG AGAGCCACAGGTGTACACC (SEQ ID NO: 18), linkH2: tgatcatacgtagatatcacggc (SEQ ID NO: 16), a reaction at 98 ° C for 1 second, 60 ° C for 30 seconds, 72 ° C for 30 seconds 15 I went twice.
- the reaction at 98 ° C for 1 second, 60 ° C for 30 seconds and 72 ° C for 30 seconds is performed 5 times to obtain primer linkH, I picked up linkH2 and reacted 15 times.
- the amplified DNA fragment was cleaved with Nhel and BamHI and replaced with the IgGl constant region of the N5KG1 vector. This expression vector was named N5KG4414.
- IgG [4/4/4 / l] uses N5KG4PE as a saddle, primer linkH: gggtacgtcctcacattcagtg atcag (SEQ ID NO: 13), CH3consR: GGTGTACACCTGTGGCTCTCGGGGCTGCCC (SEQ ID NO: 17) at 98 ° C for 1 second, 60 ° C for 30 seconds The reaction at 72 ° C for 30 seconds was performed 15 times.
- the amplified DNA fragment was cut with Nhel and BamHI and replaced with the IgGl constant region of the N5KG1 vector.
- This expression vector was named N5KG4441. [0085] Each expression vector was digested with BglII and Nhel, and the light chain variable region and heavy chain variable region of 4D11 were inserted to complete the expression vector.
- the expression vector DNA prepared in Example 1 was prepared with EndoFree Plasmid Kit (Qiagen), and free-floating 293 cells (Invitrogen Life Technologies) were used using FreeStyle (registered trademark) 293 Expression System (Invitrogen Life Technologies).
- the culture supernatant containing each antibody was obtained by transient expression.
- the culture supernatant (approximately 500 ⁇ g as IgG) filtered through a 0.22 m membrane filter (MILLIPORE) was added to HiTrap rProtein A FF (column volume lml) (Amersham Biosciences), an affinity ram for antibody purification.
- the sample was charged, washed with PBS ( ⁇ ), eluted with 20 mM citrate buffer (pH 3.4), and collected in a tube containing 200 mM phosphate buffer (pH 7.0).
- the content of aggregates in each antibody sample after purification was 0 to 0.7%.
- Aggregate content of the antibody solution is analyzed using a high performance liquid chromatograph (Shimadzu) and TSK-G3000 SW column (Tosohichi) and 20mM sodium phosphate and 500mM NaCl PH7.0 as solvents. Went.
- the molecular weight marker for gel filtration HPLC Oriental Yeast Co., Ltd.
- Cat No. 40403701 the molecular weight marker for gel filtration HPLC
- the antibody solution 300 1 purified by the method shown in Example 2 was adjusted to pH 3.5 by adding 60 / zl of a buffer (pH 2.7) consisting of 200 mM sodium citrate and 50 mM NaCl. After incubation for 10 minutes or 60 minutes at ° C, the low pH treated solution 150 1 was neutralized by adding 37.5 ⁇ l of 500 mM sodium phosphate buffer (pH 8.0). The aggregate content of the antibody solution after the low pH treatment was measured by the method shown in Example 3.
- a buffer pH 2.7
- Q355R CCTGCCCCCA TCCCGGGAGG AGATGACCAA G (SEQ ID NO: 19), E356D: CCATCCCA GGACGAGATG ACCAAGAAC (SEQ ID NO: 20), M358L: ATCCCAGGAG GAGCTGACCA AGAACCAG (SEQ ID NO: 21), R409K: CT TCTTTC TAACCGTGGA CAAG (SEQ ID NO: 22), E419Q: GAG CAGGTGG CAGCAGGGGA ATGTCTTCTC (SEQ ID NO: 23), L445P: CCTCTCCC TG TCTCCGGGTA AATGAGGATC C (SEQ ID NO: 24) were used.
- An anti-CD40 antibody expression vector (described in WO02 / 088186, Japanese Patent Application No. 2003-431408) prepared by inserting a DNA fragment containing a heavy chain and a light chain of an anti-CD40 antibody gene into an N5KG4PE vector (IDEC Pharmaceuticals)
- Various mutant DNAs encoding amino acid substitutions in the constant region were prepared by site-directed mutagenesis using the GeneEditor (registered trademark) in vitro Site-Directed Mutagenesis System (Promega) using the DNA as a saddle.
- Target mutagenesis oligo After synthesizing the mutation-introduced strand by annealing the nucleotide and the selection Oligonucleotide included in the above kit with the vertical DNA, the mutant is amplified using the fact that only the mutant grows in the presence of GeneEditor® Antibiotic Selection Mix. Selected. More specifically, dsDNA template is incubated under alkaline conditions (0.2 M NaOH, 0.2 mM EDTA (final concentration)) for 5 minutes at room temperature, and then 1/10 volume of 2M ammonium acetate (pH 4.6). After neutralization, the strength was recovered by ethanol precipitation.
- the collected alkali-denatured vertical DNA is collected into the target mutation-inducing oligonucleotide (the sequence of each oligonucleotide is shown in Table 1, 5'-terminal phosphorylated) and a new antibiotic resistance acquisition Oligonucleotide (T op Select 01igo, 5, terminal phosphorylation) and the annealing buffer attached to the kit was added, and the mixture was incubated at 75 ° C for 5 minutes and slowly lowered to 37 ° C for annealing.
- Synthesis 10X buffer, T4 DNA Polymerase, and T4 DNA ligase included in the kit were added, and the reaction was performed at 37 ° C for 90 minutes.
- Plasmid DNA is prepared from transformant Escherichia coli cultivated by transforming to the competent cell BMH 71-18 mutS in the presence of GeneEditor (registered trademark) An tibiotic Selection Mix, and then the competent cell JM 109 is transformed with the DNA. Thereafter, the cells were seeded on an LB plate containing GeneEditor (registered trademark) Antibiotic Selection Mix.
- the transformant produced on the plate is cultured, the plasmid DNA is purified, the DNA nucleotide sequence is analyzed, and the expression vector of the anti-CD40 antibody mutant into which the target amino acid mutation has been introduced (N5KG4PE-4D11-Q355R, N5KG4PE) -4D11-E356D, N5KG4PE-4D11-M358L, N5KG4PE-4D11-R409K, N5KG4PE-4D11-E419Q, N5KG4PE-4D11-L445P).
- Each antibody was expressed and purified according to Example 2, and the stability at low pH was measured according to Example 3.
- the cell suspension (100 ⁇ l 1well) was dispensed into a 96-well round bottom plate (Betaton Dickinson).
- the culture supernatant (50 ⁇ 1) of each hyperidoma was added and incubated at ice temperature for 30 minutes.
- As a negative control a HgG1 antibody against human serum albumin was used, adjusted to a concentration of 2 ⁇ g / ml in Hypridoma culture medium, and incubated at 15 ° C. for 15 minutes after addition of 50 1.
- R-PE fluorescently labeled anti-human antibody manufactured by Southern Biotechnology
- 4D11, F4-465 and KM281-1-10 are known as antagost antibodies.
- Antibody The effects of antagonist activity possessed by structural changes in the constant region were examined. In Ramos cells, CD95 expression is increased by adding CD40 ligand. At this time, the antagonist activity of the antibody was evaluated using as an index whether the increase in the expression of CD95 can be suppressed by adding the antibody.
- l.OxlO 6 cells / ml Ramos cell suspension was seeded on a 96-well plate at 50 ⁇ l / well.
- the culture supernatant or purified antibody was adjusted to 2 g / ml with the medium, and added to a 96 well plate at 100 1 / well.
- Soluble CD40 ligand (ALEXIS CORPORATION) 4 g / ml and anti-FLAG antibody (M2, Sigma) 4 g / ml were added to the medium and added to a 96-well plate at 50 ⁇ l / well. After culturing, the cells were collected and analyzed using FACS using an R-PE labeled anti-CD95 antibody (Pharmingen NJ).
- IgG4 antibodies (4D 11-G4PE [R409A], 4D 11- G4PE [R409D], 4D11- G4PE [R409E], 4D11- G4PE [R409F], 4D11- G4PE [R409G], 4D11- G 4PE [ R409H], 4D11- G4PE [R409I], 4D11- G4PE [R409L], 4D11- G4PE [R409M] ⁇ 4D1 1- G4PE [R409N], 4D11- G4PE [R409P], 4D11- G4PE [R409Q], 4D11- G4PE [ R409S], 4D11-G4PE [R409T], 4D11-G4PE [R409V], 4D11-G4PE [R409A]
- 4D11- G4PE [R409D] 4D11- G4PE [R409E]
- An expression vector for each mutant was prepared by a site-directed mutagenesis method using GeneEditor (registered trademark) in vitro Site-Directed Mutagenesis System (Promega) shown in Example 5.
- GeneEditor registered trademark
- the DNA of the anti-CD40 antibody expression vector described in WO02 / 0 88186, Japanese Patent Application 2003-431408
- the oligonucleotide for mutagenesis As phosphorylated, the underlined base is the site of amino acid mutation
- R409W preparation CTTCTTCCTCTACAGCTGGCTAACCGTGGACAAG (SEQ ID NO: 40),
- R409C For preparation of R409C: 18 kinds of oligonucleotides of CTTCTTCCTCTACAGCTGCCTAACCGTGGACAAG (SEQ ID NO: 42) were used.
- the target plasmid DNA of the mutant antibody expression vector obtained by each site-specific mutagenesis operation is subjected to DNA base sequence analysis for selection and confirmation of the entire base sequence of the antibody coding portion.
- a total of 18 types of mutant expression vectors into which amino acid mutations were introduced were obtained.
- each expression vector DNA was transferred to cultured cells according to Example 2 for protein expression.
- the antibody protein was purified from the culture supernatant. These purified antibodies were measured for stability at low pH (37 ° C) according to Example 3.
- Table 5 shows the content of aggregates produced when each antibody sample was treated at a low pH for 60 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05785180A EP1810979B1 (en) | 2004-09-22 | 2005-09-22 | STABILIZED HUMAN IgG4 ANTIBODIES |
ES05785180T ES2387312T3 (es) | 2004-09-22 | 2005-09-22 | Anticuerpos IgG4 humanos estabilizados |
CA2580981A CA2580981C (en) | 2004-09-22 | 2005-09-22 | Stabilized human igg4 antibodies |
US11/663,340 US8911726B2 (en) | 2004-09-22 | 2005-09-22 | Stabilized human Igg4 antibodies |
JP2006536409A JP4958555B2 (ja) | 2004-09-22 | 2005-09-22 | 安定化されたヒトIgG4抗体 |
US14/539,486 US9688766B2 (en) | 2004-09-22 | 2014-11-12 | Stabilized human IgG4 antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004275908 | 2004-09-22 | ||
JP2004-275908 | 2004-09-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/663,340 A-371-Of-International US8911726B2 (en) | 2004-09-22 | 2005-09-22 | Stabilized human Igg4 antibodies |
US14/539,486 Continuation US9688766B2 (en) | 2004-09-22 | 2014-11-12 | Stabilized human IgG4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006033386A1 true WO2006033386A1 (ja) | 2006-03-30 |
Family
ID=36090141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017463 WO2006033386A1 (ja) | 2004-09-22 | 2005-09-22 | 安定化されたヒトIgG4抗体 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8911726B2 (ja) |
EP (1) | EP1810979B1 (ja) |
JP (1) | JP4958555B2 (ja) |
CA (1) | CA2580981C (ja) |
ES (1) | ES2387312T3 (ja) |
WO (1) | WO2006033386A1 (ja) |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008134046A1 (en) * | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
WO2008145142A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
US20100306867A1 (en) * | 2007-05-31 | 2010-12-02 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
JP2011509245A (ja) * | 2007-12-26 | 2011-03-24 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする剤及びその使用 |
WO2011052799A1 (en) * | 2009-10-30 | 2011-05-05 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating inflammatory disorders |
WO2011108502A1 (ja) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | 改変抗体組成物 |
WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
WO2011147982A2 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 epitope |
WO2011147986A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
WO2011157741A2 (en) | 2010-06-15 | 2011-12-22 | Genmab A/S | Human antibody drug conjugates against tissue factor |
JP2012502622A (ja) * | 2008-06-20 | 2012-02-02 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
JP2012510282A (ja) * | 2008-12-03 | 2012-05-10 | ゲンマブ エー/エス | 定常領域の中に改変を有する抗体変種 |
US8188249B2 (en) | 2003-09-10 | 2012-05-29 | Amgen Fremont Inc. | Nucleic acid molecules encoding antibodies to M-CSF |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
WO2012171057A1 (en) | 2011-06-13 | 2012-12-20 | Csl Limited | Antibodies against g-csfr and uses thereof |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
WO2013014092A1 (en) | 2011-07-22 | 2013-01-31 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
WO2013030799A1 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag. | B cell assay |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2015152430A1 (en) * | 2014-04-04 | 2015-10-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity |
US9181344B2 (en) | 2005-12-15 | 2015-11-10 | Genmab A/S | Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228020B2 (en) | 2006-09-29 | 2016-01-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
JP2016106105A (ja) * | 2006-09-01 | 2016-06-16 | ザイモジェネティクス, インコーポレイテッド | Il−31モノクローナル抗体の可変領域配列と使用方法 |
WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
WO2016135066A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
US9480744B2 (en) | 2010-09-10 | 2016-11-01 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US9511139B2 (en) | 2009-10-16 | 2016-12-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
EP3159358A1 (en) | 2008-12-09 | 2017-04-26 | Genmab A/S | Human antibodies against human tissue factor |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
JP2017519494A (ja) * | 2014-05-29 | 2017-07-20 | メディミューン,エルエルシー | Ox40l融合タンパク質およびその使用 |
WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
WO2017162678A1 (en) | 2016-03-22 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humanized anti-claudin-1 antibodies and uses thereof |
WO2017191300A1 (en) | 2016-05-06 | 2017-11-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9922164B2 (en) | 2008-06-20 | 2018-03-20 | Novartis Ag | Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor |
US9957329B2 (en) | 2012-01-31 | 2018-05-01 | Csl Behring Gmbh | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
WO2019057933A1 (en) | 2017-09-21 | 2019-03-28 | Imcheck Therapeutics Sas | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
WO2019093342A1 (ja) | 2017-11-08 | 2019-05-16 | 協和発酵キリン株式会社 | CD40とEpCAMに結合するバイスペシフィック抗体 |
WO2019104385A1 (en) | 2017-11-29 | 2019-06-06 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
WO2019117208A1 (ja) | 2017-12-12 | 2019-06-20 | 協和発酵キリン株式会社 | 抗bmp10抗体及び該抗体を有効成分とする、高血圧および高血圧性疾患に対する治療剤 |
US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
WO2020004490A1 (ja) | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン-5に結合する抗体 |
WO2020004492A1 (ja) | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | Cell Adhesion Molecule3に結合する抗体 |
JP2020505013A (ja) * | 2017-01-06 | 2020-02-20 | エルサリー バイオテックElsalysbiotech | ヒトcd160を結合する結合物及びその使用 |
JP2020509761A (ja) * | 2017-03-14 | 2020-04-02 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 免疫グロブリンのFc部分を含む二重標的融合タンパク質 |
WO2020138487A1 (ja) | 2018-12-28 | 2020-07-02 | 協和キリン株式会社 | TfRに結合するバイスペシフィック抗体 |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
WO2020188086A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
WO2020230901A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とgpc3に結合するバイスペシフィック抗体 |
WO2020230899A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とfapに結合するバイスペシフィック抗体 |
WO2021009263A1 (en) | 2019-07-16 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for cd38 and uses thereof |
WO2021049606A1 (ja) | 2019-09-13 | 2021-03-18 | 協和キリン株式会社 | DcR3改変体 |
WO2021058763A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11046760B2 (en) | 2014-10-31 | 2021-06-29 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2021162098A1 (ja) | 2020-02-14 | 2021-08-19 | 協和キリン株式会社 | Cd3に結合するバイスペシフィック抗体 |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11174321B2 (en) | 2016-04-06 | 2021-11-16 | Csl Limited | Method of treating atherosclerosis |
WO2021234402A2 (en) | 2020-05-21 | 2021-11-25 | Mabsolve Limited | Modified immunoglobulin fc regions |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
WO2023027177A1 (ja) | 2021-08-26 | 2023-03-02 | 協和キリン株式会社 | Cd116およびcd131に結合するバイスペシフィック抗体 |
US11634495B2 (en) | 2017-04-07 | 2023-04-25 | Miltenyi Biotec B.V. & Co. KG | Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303) |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
EP4219552A2 (en) | 2013-02-07 | 2023-08-02 | CSL Ltd. | Il-11r binding proteins and uses thereof |
US11725048B2 (en) | 2019-12-20 | 2023-08-15 | Hudson Institute of Medical Research | CXCL10 binding proteins and compositions thereof |
WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
US12037380B2 (en) | 2020-05-21 | 2024-07-16 | Mabsol Ve Limited | Modified immunoglobulin Fc regions |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2387312T3 (es) * | 2004-09-22 | 2012-09-20 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos IgG4 humanos estabilizados |
EP1806145B1 (en) | 2004-10-29 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Remedy for inflammatory diseases |
JP4986633B2 (ja) | 2005-01-12 | 2012-07-25 | 協和発酵キリン株式会社 | 安定化されたヒトIgG2およびIgG3抗体 |
KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
JP5817034B2 (ja) | 2007-12-26 | 2015-11-18 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする免疫複合体及びその使用 |
AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
CN102458479B (zh) | 2009-06-04 | 2016-07-13 | 诺华公司 | 识别IgG结合位点的方法 |
SG183983A1 (en) | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
HUE044591T2 (hu) | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
EP2771364B1 (en) | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
MX2016003292A (es) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos. |
CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
AU2015292678B2 (en) | 2014-07-22 | 2020-10-22 | Cb Therapeutics, Inc. | Anti-PD-1 antibodies |
CA2956399A1 (en) | 2014-08-05 | 2016-02-11 | Cb Therapeutics, Inc. | Anti-pd-l1 antibodies |
CN104292341B (zh) * | 2014-10-11 | 2018-08-10 | 上海兴迪金生物技术有限公司 | 一种凝血八因子融合蛋白及其制备方法和用途 |
KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
WO2016097300A1 (en) | 2014-12-19 | 2016-06-23 | Genmab A/S | Rodent bispecific heterodimeric proteins |
SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
EP3443000A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
DK3500299T3 (da) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
KR102661060B1 (ko) * | 2017-07-06 | 2024-04-25 | 니토 보세키 가부시기가이샤 | 항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약 |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
CA3078517A1 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
US20230101432A1 (en) | 2018-01-03 | 2023-03-30 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
CN112638417A (zh) * | 2018-06-22 | 2021-04-09 | 奥默罗斯公司 | 用于治疗各种血栓性疾病和病症的抑制masp-2的组合物和方法 |
JP2022510276A (ja) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd86バリアント免疫調節タンパク質およびその使用 |
WO2020214867A1 (en) | 2019-04-17 | 2020-10-22 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
JP2022533855A (ja) * | 2019-05-30 | 2022-07-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 抗TrkA抗体及びその使用 |
AU2021268033A1 (en) | 2020-05-08 | 2022-12-15 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof |
CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
CA3212056A1 (en) | 2021-03-22 | 2022-09-29 | Xavier CHAUCHET | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
EP4333869A1 (en) | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512776A (ja) * | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
WO2002088186A1 (en) * | 2001-04-27 | 2002-11-07 | Kirin Beer Kabushiki Kaisha | Anti-cd40 monoclonal antibody |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376653B1 (en) * | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
US6998124B1 (en) * | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
ES2387312T3 (es) * | 2004-09-22 | 2012-09-20 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos IgG4 humanos estabilizados |
-
2005
- 2005-09-22 ES ES05785180T patent/ES2387312T3/es active Active
- 2005-09-22 WO PCT/JP2005/017463 patent/WO2006033386A1/ja active Application Filing
- 2005-09-22 EP EP05785180A patent/EP1810979B1/en active Active
- 2005-09-22 CA CA2580981A patent/CA2580981C/en active Active
- 2005-09-22 US US11/663,340 patent/US8911726B2/en active Active
- 2005-09-22 JP JP2006536409A patent/JP4958555B2/ja active Active
-
2014
- 2014-11-12 US US14/539,486 patent/US9688766B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512776A (ja) * | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
WO2002088186A1 (en) * | 2001-04-27 | 2002-11-07 | Kirin Beer Kabushiki Kaisha | Anti-cd40 monoclonal antibody |
Non-Patent Citations (1)
Title |
---|
BRUSCO A ET AL: "Molecular characterization of immunoglobulin G4 gene isoallotypes.", EUR J IMMUNOGENET., vol. 25, no. 5, 1998, pages 349 - 355, XP002995211 * |
Cited By (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9718883B2 (en) | 2003-09-10 | 2017-08-01 | Amgen Fremont Inc. | Antibodies to M-CSF |
US10280219B2 (en) | 2003-09-10 | 2019-05-07 | Amgen Fremont Inc. | Antibodies to M-CSF |
US8188249B2 (en) | 2003-09-10 | 2012-05-29 | Amgen Fremont Inc. | Nucleic acid molecules encoding antibodies to M-CSF |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US9181344B2 (en) | 2005-12-15 | 2015-11-10 | Genmab A/S | Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP2016106105A (ja) * | 2006-09-01 | 2016-06-16 | ザイモジェネティクス, インコーポレイテッド | Il−31モノクローナル抗体の可変領域配列と使用方法 |
US9376497B2 (en) | 2006-09-29 | 2016-06-28 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US9228020B2 (en) | 2006-09-29 | 2016-01-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
EP2599791A1 (en) * | 2007-04-27 | 2013-06-05 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-CD4 antibodies |
EP3067368A1 (en) * | 2007-04-27 | 2016-09-14 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
WO2008134046A1 (en) * | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
JP2014122226A (ja) * | 2007-05-31 | 2014-07-03 | Genmab As | 安定なIgG4抗体 |
AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
JP2017071606A (ja) * | 2007-05-31 | 2017-04-13 | ゲンマブ エー/エス | 安定なIgG4抗体 |
EP4119579A1 (en) | 2007-05-31 | 2023-01-18 | Genmab A/S | Stable igg4 antibodies |
US9322035B2 (en) * | 2007-05-31 | 2016-04-26 | Genmab A/S | Recombinant IgG4 monovalent antibodies |
US10752695B2 (en) | 2007-05-31 | 2020-08-25 | Genmab A/S | Stable IgG4 antibodies |
WO2008145142A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
US20100306867A1 (en) * | 2007-05-31 | 2010-12-02 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
JP2010528993A (ja) * | 2007-05-31 | 2010-08-26 | ゲンマブ エー/エス | 安定なIgG4抗体 |
US10351629B2 (en) | 2007-05-31 | 2019-07-16 | Genmab A/S | Recombinant IgG4 monovalent antibodies |
EP2666787A1 (en) * | 2007-05-31 | 2013-11-27 | Genmab A/S | Stable IgG4 antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
JP2011509245A (ja) * | 2007-12-26 | 2011-03-24 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする剤及びその使用 |
JP2015143228A (ja) * | 2007-12-26 | 2015-08-06 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする剤及びその使用 |
JP2015107126A (ja) * | 2008-06-20 | 2015-06-11 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
JP2017071627A (ja) * | 2008-06-20 | 2017-04-13 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
US9922164B2 (en) | 2008-06-20 | 2018-03-20 | Novartis Ag | Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor |
JP2019000121A (ja) * | 2008-06-20 | 2019-01-10 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
JP2012502622A (ja) * | 2008-06-20 | 2012-02-02 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
JP2012510282A (ja) * | 2008-12-03 | 2012-05-10 | ゲンマブ エー/エス | 定常領域の中に改変を有する抗体変種 |
EP3159358A1 (en) | 2008-12-09 | 2017-04-26 | Genmab A/S | Human antibodies against human tissue factor |
EP4279140A2 (en) | 2008-12-09 | 2023-11-22 | Genmab A/S | Human antibodies against tissue factor |
US10066018B2 (en) | 2009-03-19 | 2018-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US9309311B2 (en) | 2009-04-27 | 2016-04-12 | Oncomed Pharmaceuticals, Inc. | Method for making Heteromultimeric molecules |
US9914771B2 (en) | 2009-04-27 | 2018-03-13 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US9982042B2 (en) | 2009-10-16 | 2018-05-29 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US10870693B2 (en) | 2009-10-16 | 2020-12-22 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US9511139B2 (en) | 2009-10-16 | 2016-12-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
WO2011052799A1 (en) * | 2009-10-30 | 2011-05-05 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating inflammatory disorders |
JP2015027304A (ja) * | 2009-10-30 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 炎症性疾患を処置するための組成物および方法 |
US8932592B2 (en) | 2009-10-30 | 2015-01-13 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating inflammatory disorders |
JP2013509158A (ja) * | 2009-10-30 | 2013-03-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 炎症性疾患を処置するための組成物および方法 |
WO2011108502A1 (ja) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | 改変抗体組成物 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
JP5889181B2 (ja) * | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP3511342A1 (en) | 2010-03-10 | 2019-07-17 | Genmab A/S | Monoclonal antibodies against c-met |
EP3904391A1 (en) | 2010-03-10 | 2021-11-03 | Genmab A/S | Monoclonal antibodies against c-met |
WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
WO2011147986A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
US11091553B2 (en) | 2010-05-27 | 2021-08-17 | Genmab A/S | Monoclonal antibodies against HER2 |
WO2011147982A2 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 epitope |
US11046771B2 (en) | 2010-05-27 | 2021-06-29 | Genmab A/S | Monoclonal antibodies against HER2 |
EP3539988A2 (en) | 2010-05-27 | 2019-09-18 | Genmab A/S | Monoclonal antibodies against her2 |
EP3613774A1 (en) | 2010-06-09 | 2020-02-26 | Genmab A/S | Antibodies against human cd38 |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
EP3281956A2 (en) | 2010-06-15 | 2018-02-14 | Genmab A/S | Human antibody drug conjugates against tissue factor |
WO2011157741A2 (en) | 2010-06-15 | 2011-12-22 | Genmab A/S | Human antibody drug conjugates against tissue factor |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
US9480744B2 (en) | 2010-09-10 | 2016-11-01 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US11578141B2 (en) | 2011-04-20 | 2023-02-14 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
WO2012171057A1 (en) | 2011-06-13 | 2012-12-20 | Csl Limited | Antibodies against g-csfr and uses thereof |
US9856325B2 (en) | 2011-07-22 | 2018-01-02 | Csl Behring Gmbh | Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
WO2013014092A1 (en) | 2011-07-22 | 2013-01-31 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
US11345759B2 (en) | 2011-07-22 | 2022-05-31 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies |
US10513560B2 (en) | 2011-07-22 | 2019-12-24 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies |
US9518127B2 (en) | 2011-07-22 | 2016-12-13 | Csl Behring Gmbh | Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses |
US9856326B2 (en) | 2011-07-22 | 2018-01-02 | Csl Behring Gmbh | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies |
WO2013030799A1 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag. | B cell assay |
US9376488B2 (en) | 2011-09-23 | 2016-06-28 | Oncomed Pharmaceuticals, Inc. | VEGF binding antibodies |
US9879084B2 (en) | 2011-09-23 | 2018-01-30 | Oncomed Pharmaceuticals, Inc. | Modified immunoglobulin molecules that specifically bind human VEGF and DLL4 |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US11512128B2 (en) | 2011-09-23 | 2022-11-29 | Mereo Biopharma 5, Inc. | VEGF/DLL4 binding agents and uses thereof |
US9574009B2 (en) | 2011-09-23 | 2017-02-21 | Oncomed Pharmaceuticals, Inc. | Polynucleotides encoding VEGF/DLL4 binding agents |
US10730940B2 (en) | 2011-09-23 | 2020-08-04 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US9957329B2 (en) | 2012-01-31 | 2018-05-01 | Csl Behring Gmbh | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
EP4219552A2 (en) | 2013-02-07 | 2023-08-02 | CSL Ltd. | Il-11r binding proteins and uses thereof |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
US10973891B2 (en) | 2013-03-08 | 2021-04-13 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
WO2015152430A1 (en) * | 2014-04-04 | 2015-10-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity |
JP2017519494A (ja) * | 2014-05-29 | 2017-07-20 | メディミューン,エルエルシー | Ox40l融合タンパク質およびその使用 |
US11046760B2 (en) | 2014-10-31 | 2021-06-29 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
WO2016135066A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
WO2017162678A1 (en) | 2016-03-22 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humanized anti-claudin-1 antibodies and uses thereof |
US11174321B2 (en) | 2016-04-06 | 2021-11-16 | Csl Limited | Method of treating atherosclerosis |
EP3744348A1 (en) | 2016-05-06 | 2020-12-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
WO2017191300A1 (en) | 2016-05-06 | 2017-11-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
JP7189878B2 (ja) | 2017-01-06 | 2022-12-14 | エルサリー バイオテック | ヒトcd160を結合する結合物及びその使用 |
JP2020505013A (ja) * | 2017-01-06 | 2020-02-20 | エルサリー バイオテックElsalysbiotech | ヒトcd160を結合する結合物及びその使用 |
JP7181886B2 (ja) | 2017-03-14 | 2022-12-01 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 免疫グロブリンのFc部分を含む二重標的融合タンパク質 |
JP2020509761A (ja) * | 2017-03-14 | 2020-04-02 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 免疫グロブリンのFc部分を含む二重標的融合タンパク質 |
US11634495B2 (en) | 2017-04-07 | 2023-04-25 | Miltenyi Biotec B.V. & Co. KG | Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303) |
WO2019057933A1 (en) | 2017-09-21 | 2019-03-28 | Imcheck Therapeutics Sas | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF |
JPWO2019093342A1 (ja) * | 2017-11-08 | 2020-11-26 | 協和キリン株式会社 | CD40とEpCAMに結合するバイスペシフィック抗体 |
US11773180B2 (en) | 2017-11-08 | 2023-10-03 | Kyowa Kirin Co., Ltd. | Bispecific antibody which binds to CD40 and EpCAM |
WO2019093342A1 (ja) | 2017-11-08 | 2019-05-16 | 協和発酵キリン株式会社 | CD40とEpCAMに結合するバイスペシフィック抗体 |
JP7311425B2 (ja) | 2017-11-08 | 2023-07-19 | 協和キリン株式会社 | CD40とEpCAMに結合するバイスペシフィック抗体 |
WO2019104385A1 (en) | 2017-11-29 | 2019-06-06 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
WO2019117208A1 (ja) | 2017-12-12 | 2019-06-20 | 協和発酵キリン株式会社 | 抗bmp10抗体及び該抗体を有効成分とする、高血圧および高血圧性疾患に対する治療剤 |
WO2020004490A1 (ja) | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン-5に結合する抗体 |
WO2020004492A1 (ja) | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | Cell Adhesion Molecule3に結合する抗体 |
WO2020138487A1 (ja) | 2018-12-28 | 2020-07-02 | 協和キリン株式会社 | TfRに結合するバイスペシフィック抗体 |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
WO2020188086A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
WO2020230899A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とfapに結合するバイスペシフィック抗体 |
WO2020230901A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とgpc3に結合するバイスペシフィック抗体 |
WO2021009263A1 (en) | 2019-07-16 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for cd38 and uses thereof |
WO2021049606A1 (ja) | 2019-09-13 | 2021-03-18 | 協和キリン株式会社 | DcR3改変体 |
WO2021058763A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
US11725048B2 (en) | 2019-12-20 | 2023-08-15 | Hudson Institute of Medical Research | CXCL10 binding proteins and compositions thereof |
WO2021162098A1 (ja) | 2020-02-14 | 2021-08-19 | 協和キリン株式会社 | Cd3に結合するバイスペシフィック抗体 |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
WO2021234402A2 (en) | 2020-05-21 | 2021-11-25 | Mabsolve Limited | Modified immunoglobulin fc regions |
US12037380B2 (en) | 2020-05-21 | 2024-07-16 | Mabsol Ve Limited | Modified immunoglobulin Fc regions |
WO2023027177A1 (ja) | 2021-08-26 | 2023-03-02 | 協和キリン株式会社 | Cd116およびcd131に結合するバイスペシフィック抗体 |
WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US20080063635A1 (en) | 2008-03-13 |
ES2387312T3 (es) | 2012-09-20 |
US20150141621A1 (en) | 2015-05-21 |
CA2580981A1 (en) | 2006-03-30 |
EP1810979A4 (en) | 2008-12-24 |
CA2580981C (en) | 2013-10-22 |
US8911726B2 (en) | 2014-12-16 |
EP1810979A1 (en) | 2007-07-25 |
EP1810979B1 (en) | 2012-06-20 |
JPWO2006033386A1 (ja) | 2008-05-15 |
JP4958555B2 (ja) | 2012-06-20 |
US9688766B2 (en) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4958555B2 (ja) | 安定化されたヒトIgG4抗体 | |
CN111138545B (zh) | 针对cd20和cd3的双特异性抗体及其用途 | |
JP4986633B2 (ja) | 安定化されたヒトIgG2およびIgG3抗体 | |
KR101760242B1 (ko) | 항-cd40 항체 | |
JP2018126150A (ja) | Tl1aと結合する抗体およびその使用 | |
WO2005063981A1 (ja) | 抗cd40抗体の変異体 | |
US20220112298A1 (en) | Novel anti-cd4o antibodies and use thereof | |
CN113614109A (zh) | 双功能抗pd-1/il-7分子 | |
JP2017536101A (ja) | Ccr6と結合する抗体およびその使用 | |
WO2020207470A1 (zh) | 抗cd40抗体及其用途 | |
KR20230078657A (ko) | 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물 | |
JP2021523688A (ja) | 抗cd27抗体およびその使用 | |
MXPA06006760A (en) | Mutants of anti-cd40 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006536409 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2580981 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005785180 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005785180 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11663340 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11663340 Country of ref document: US |